Is Buying Viking Therapeutics, Inc. (VKTX) Here a Winning Strategy?

December 26, 2017 - By Adrian Erickson

The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) is a huge mover today! The stock increased 2.48% or $0.1 during the last trading session, reaching $4.14. About 435,659 shares traded. Viking Therapeutics, Inc. (NASDAQ:VKTX) has risen 5.04% since December 26, 2016 and is uptrending. It has underperformed by 11.66% the S&P500.
The move comes after 5 months positive chart setup for the $145.15M company. It was reported on Dec, 26 by We have $4.51 PT which if reached, will make NASDAQ:VKTX worth $13.06 million more.

Analysts await Viking Therapeutics, Inc. (NASDAQ:VKTX) to report earnings on March, 20. They expect $-0.19 earnings per share, down 5.56 % or $0.01 from last year’s $-0.18 per share. After $-0.22 actual earnings per share reported by Viking Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -13.64 % EPS growth.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

Among 4 analysts covering Viking Therapeutics (NASDAQ:VKTX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics had 11 analyst reports since April 7, 2016 according to SRatingsIntel. The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) earned “Buy” rating by Maxim Group on Tuesday, June 6. H.C. Wainwright maintained the shares of VKTX in report on Thursday, August 10 with “Buy” rating. The rating was maintained by Roth Capital with “Buy” on Wednesday, November 29. H.C. Wainwright maintained it with “Buy” rating and $700 target in Monday, July 17 report. The firm has “Buy” rating given on Wednesday, July 12 by Maxim Group. The firm earned “Buy” rating on Thursday, April 7 by H.C. Wainwright. On Tuesday, November 21 the stock rating was initiated by Roth Capital with “Buy”. Laidlaw maintained the shares of VKTX in report on Thursday, August 11 with “Buy” rating. Maxim Group initiated the shares of VKTX in report on Tuesday, May 24 with “Buy” rating. Maxim Group maintained the shares of VKTX in report on Thursday, August 10 with “Buy” rating.

More important recent Viking Therapeutics, Inc. (NASDAQ:VKTX) news were published by: which released: “Viking Therapeutics Announces Proposed Public Offering of Common Stock” on December 05, 2017, also published article titled: “Viking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/Sh”, published: “Madrigal’s mid-stage success with NASH candidate MGL-3196 stokes Viking …” on December 06, 2017. More interesting news about Viking Therapeutics, Inc. (NASDAQ:VKTX) was released by: and their article: “Pre-market Technical Scan on Biotech Equities — Viking Therapeutics, RXi …” with publication date: December 04, 2017.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. The company has market cap of $145.15 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. It currently has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.